| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.074 | 0.04 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.078 | 0.04 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.04 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.04 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.04 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.12 | 0.05 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.05 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | 0.068 | 0.05 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.081 | 0.05 |